Summit Therapeutics SMMT Total Operating Expenses
Total Operating Expenses at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's total operating expenses?
- Summit Therapeutics (SMMT) reported total operating expenses of $195.21M in Q1 2026.
- How has Summit Therapeutics's total operating expenses changed year-over-year?
- Summit Therapeutics's total operating expenses increased by 192.0% year-over-year, from $66.85M to $195.21M.
- What is the long-term trend for Summit Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Summit Therapeutics's total operating expenses has grown at a 78.0% compound annual growth rate (CAGR), from $108.96M to $1.09B.
- What does total operating expenses mean?
- The total cost of operating the business during a specific period.
- How do you interpret total operating expenses?
- An increase indicates higher operational spending, which must be balanced against revenue growth or pipeline progress to ensure sustainability.
- How does total operating expenses compare across companies?
- Used to compare the overall cost structure and burn rate against similar-stage biopharmaceutical companies.